In vivo evaluation of drug-drug interaction via mechanism-based inhibition by macrolide antibiotics in cynomolgus monkeys

Drug Metabolism and Disposition

Volumn 37, Issue 11, 2009, Pages 2127-2136

  Ogasawara, Akihito ^a   Negishi, Isao ^a   Kozakai, Kazumasa ^a   Kume, Toshiyuki ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; AZITHROMYCIN; CLARITHROMYCIN; CYTOCHROME P450 3A; ERYTHROMYCIN; MIDAZOLAM;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; EXPERIMENTAL MONKEY; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; INCUBATION TIME; LIVER MICROSOME; MALE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE;

ANIMALS; ANTI-BACTERIAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; MACACA FASCICULARIS; MACROLIDES; MALE; MICROSOMES;

ANIMALIA; MACACA FASCICULARIS;

EID: 70350314827     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.028969     Document Type: Article

References (39)

1. Barzaghi N, Gatti G, Crema F, Monteleone M, Amione C, Leone L, and Perucca E (1987) Inhibition by erythromycin of the conversion of carbamazepine to its active 10,11-epoxide metabolite. Br J Clin Pharmacol 24:836-838. (Pubitemid 18078393)
2. Freeman DJ, Martell R, Carruthers SG, Heinrichs D, Keown PA, and Stiller CR (1987) Cyclosporin-erythromycin interaction in normal subjects. Br J Clin Pharmacol 23:776-778.
3. Galetin A, Burt H, Gibbons L, and Houston JB (2006) Prediction of time-dependent CYP3A4 drug-drug interactions: impact of enzyme degradation, parallel elimination pathways, and intestinal inhibition. Drug Metab Dispos 34:166-175. (Pubitemid 43042658)
4. Gorski JC, Hall SD, Jones DR, VandenBranden M, and Wrighton SA (1994) Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47:1643-1653. (Pubitemid 24167278)
5. Gorski JC, Jones DR, Haehner-Daniels BD, Hamman MA, O'Mara EM Jr, and Hall SD (1998) The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther 64:133-143.
6. Greenblatt DJ, von Moltke LL, Harmatz JS, Counihan M, Graf JA, Durol AL, Mertzanis P, Duan SX, Wright CE, and Shader RI (1998) Inhibition of triazolam clearance by macrolide antimicrobial agents: in vitro correlates and dynamic consequences. Clin Pharmacol Ther 64:278-285. (Pubitemid 28462288)
7. Ishigami M, Kawabata K, Takasaki W, Ikeda T, Komai T, Ito K, and Sugiyama Y (2001) Drug interaction between simvastatin and itraconazole in male and female rats. Drug Metab Dispos 29:1068-1072. (Pubitemid 32605924)
8. Ito K, Ogihara K, Kanamitsu S, and Itoh T (2003) Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab Dispos 31:945-954. (Pubitemid 36759066)
9. Jain R and Danziger LH (2004) The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des 10:3045-3053. (Pubitemid 39242900)
10. Kanazu T, Yamaguchi Y, Okamura N, Baba T, and Koike M (2004) Model for the drug-drug interaction responsible for CYP3A enzyme inhibition. I: evaluation of cynomolgus monkeys as surrogates for humans. Xenobiotica 34:391-402. (Pubitemid 38901450)
11. Komori M, Kikuchi O, Sakuma T, Funaki J, Kitada M, and Kamataki T (1992) Molecular cloning of monkey liver cytochrome P-450 cDNAs: similarity of the primary sequences to human cytochromes P-450. Biochim Biophys Acta 1171:141-146. (Pubitemid 23023701)
12. Komura H and Iwaki M (2008) Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates. J Pharm Sci 97:1775-1800.
13. Kotegawa T, Laurijssens BE, Von Moltke LL, Cotreau MM, Perloff MD, Venkatakrishnan K, Warrington JS, Granda BW, Harmatz JS, and Greenblatt DJ (2002) In vitro, pharmacokinetic, and pharmacodynamic interactions of ketoconazole and midazolam in the rat. J Pharmacol Exp Ther 302:1228-1237. (Pubitemid 34920247)
14. Lim HK, Duczak N Jr, Brougham L, Elliot M, Patel K, and Chan K (2005) Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab Dispos 33:1211-1219. (Pubitemid 41043765)
15. Mankowski DC, Laddison KJ, Christopherson PA, Ekins S, Tweedie DJ, and Lawton MP (1999) Molecular cloning, expression, and characterization of CYP2D17 from cynomolgus monkey liver. Arch Biochem Biophys 372:189-196.
16. Mayhew BS, Jones DR, and Hall SD (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos 28:1031-1037.
17. Mori K, Hashimoto H, Takatsu H, Tsuda-Tsukimoto M, and Kume T (2009) Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development. Xenobiotica 39:415-422.
18. Obach RS, Walsky RL, and Venkatakrishnan K (2007) Mechanism-based inactivation of human cytochrome P450 enzymes and the prediction of drug-drug interactions. Drug Metab Dispos 35:246-255. (Pubitemid 46148737)
19. Ogasawara A, Kume T, and Kazama E (2007) Effect of oral ketoconazole on intestinal first-pass effect of midazolam and fexofenadine in cynomolgus monkeys. Drug Metab Dispos 35:410-418. (Pubitemid 46333904)
20. Ogasawara A, Utoh M, Nii K, Ueda A, Yoshikawa T, Kume T, and Fukuzaki K (2009) Effect of oral ketoconazole on oral and intravenous pharmacokinetics of simvastatin and its acid in cynomolgus monkeys. Drug Metab Dispos 37:122-128.
21. Okudaira T, Kotegawa T, Imai H, Tsutsumi K, Nakano S, and Ohashi K (2007) Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans. J Clin Pharmacol 47:871-876.
22. Olkkola KT, Aranko K, Luurila H, Hiller A, Saarnivaara L, Himberg JJ, and Neuvonen PJ (1993) A potentially hazardous interaction between erythromycin and midazolam. Clin Pharmacol Ther 53:298-305. (Pubitemid 23094372)
23. Periti P, Mazzei T, Mini E, and Novelli A (1989) Clinical pharmacokinetic properties of the macrolide antibiotics. Effects of age and various pathophysiological states (Part I). Clin Pharmacokinet 16:193-214. (Pubitemid 19114712)
24. Periti P, Mazzei T, Mini E, and Novelli A (1992) Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 23:106-1231.
25. Pessayre D, Larrey D, Funck-Brentano C, and Benhamou JP (1985) Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother 16 (Suppl A):181-194. (Pubitemid 16246743)
26. Polasek TM and Miners JO (2006) Quantitative prediction of macrolide drug-drug interaction potential from in vitro studies using testosterone as the human cytochrome P4503A substrate. Eur J Clin Pharmacol 62:203-208.
27. Prueksaritanont T, Kuo Y, Tang C, Li C, Qiu Y, Lu B, Strong-Basalyga K, Richards K, Carr B, and Lin JH (2006) In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. Drug Metab Dispos 34:1546-1555. (Pubitemid 44285397)
28. Rogers R and Prpic R (1998) Profound symptomatic bradycardia associated with combined mibefradil and beta-blocker therapy. Med J Aust 169:425-427.
29. Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, and Haefeli WE (1998) Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 351:1929-1930. (Pubitemid 28297454)
30. Sekiguchi N, Kato M, Takada M, Watanabe H, Higashida A, Sakai S, Ishigai M, and Aso Y (2008) In vivo approach for the evaluation of mechanism-based inhibition of cytochrome P450 3A in rats. Xenobiotica 38:368-381.
31. Silverman RB (1988) Mechanism-based enzyme inactivation, in Chemistry and Enzymology vol 1, pp 3-30, CRC Press LLC, Boca Raton, FL.
32. Takedomi S, Matsuo H, Yamano K, Ohtani H, and Sawada Y (2001) In-vivo kinetics of the interaction between midazolam and erythromycin in rats, taking account of metabolic intermediate complex formation. J Pharm Pharmacol 53:643-651. (Pubitemid 32457815)
33. Traunmüller F, Zeitlinger M, Zeleny P, Müller M, and Joukhadar C (2007) Pharmacokinetics of single- and multiple-dose oral clarithromycin in soft tissues determined by microdialysis. Antimicrob Agents Chemother 51:3185-3189. (Pubitemid 350067526)
34. Uno Y, Hosaka S, Matsuno K, Nakamura C, Kito G, Kamataki T, and Nagata R (2007) Characterization of cynomolgus monkey cytochrome P450 (CYP) cDNAs: is CYP2C76 the only monkey-specific CYP gene responsible for species differences in drug metabolism? Arch Biochem Biophys 466:98-105. (Pubitemid 47405072)
35. Wang YH, Jones DR, and Hall SD (2004) Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos 32:259-266.
36. Ward KW and Smith BR (2004) A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog, and monkey to humans. I. Clearance. Drug Metab Dispos 32:603-611. (Pubitemid 38668152)
37. Watanabe A, Nakamura K, Okudaira N, Okazaki O, and Sudo K (2007) Risk assessment for drug-drug interaction caused by metabolism-based inhibition of CYP3A using automated in vitro assay systems and its application in the early drug discovery process. Drug Metab Dispos 35:1232-1238. (Pubitemid 46956447)
38. Zimmermann T, Yeates RA, Laufen H, Scharpf F, Leitold M, and Wildfeuer A (1996) Influence of the antibiotics erythromycin and azithromycin on the pharmacokinetics and pharmacodynamics of midazolam. Arzneimittelforschung 46:213-217. (Pubitemid 26080111)
39. Zhou S, Chan E, Li X, and Huang M (2005) Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Ther Clin Risk Manag 1:3-13.